Renal & Urology Medicines in India | Kasdap Healthcare

Renal and Urological Health in India: The Hidden Epidemic

Chronic Kidney Disease (CKD) is one of the most underdiagnosed conditions in India. An estimated 17% of the adult Indian population — approximately 220 million people — has some degree of kidney disease, yet the vast majority remain undiagnosed until they reach advanced stages. By the time many patients receive a diagnosis, they are already in moderate-to-severe CKD, facing a trajectory toward dialysis or transplantation.

The key drivers of CKD in India are diabetes (diabetic nephropathy), hypertension (hypertensive nephropathy), and chronic glomerulonephritis. India's diabetes epidemic alone means that renal complications will remain a major public health challenge for decades.

CKD Management: Slowing Progression

Renin-Angiotensin-Aldosterone System (RAAS) Blockade

ACE inhibitors (Ramipril, Enalapril, Lisinopril) and Angiotensin Receptor Blockers (Losartan, Telmisartan, Olmesartan) are the cornerstone of nephroprotective therapy in CKD, particularly in patients with proteinuria. By reducing intraglomerular pressure and blocking the pro-fibrotic effects of angiotensin II, they slow the rate of GFR decline and reduce proteinuria.

RAAS blockade is first-line therapy in diabetic nephropathy regardless of blood pressure, given the additional renal protective benefits beyond blood pressure lowering. However, renal function and serum potassium must be monitored after initiation and at regular intervals.

SGLT2 Inhibitors: The New Nephroprotective Standard

The landmark CREDENCE and DAPA-CKD trials established SGLT2 inhibitors (Canagliflozin, Dapagliflozin, Empagliflozin) as nephroprotective agents in CKD, independent of their glucose-lowering effects. They are now recommended across major nephrology guidelines for CKD patients with or without diabetes, based on their ability to reduce eGFR decline, proteinuria, and kidney failure events.

Blood Pressure Management in CKD

Target blood pressure in CKD is below 130/80 mmHg according to current guidelines (KDIGO 2021). Most CKD patients require combination antihypertensive therapy. RAAS blockers are the first choice, with calcium channel blockers, diuretics (loop diuretics as GFR declines), and beta-blockers added as needed.

Managing CKD Complications

As CKD progresses, multiple complications emerge requiring specific pharmacological management:

• Anaemia of CKD: Iron supplementation (oral IPC or IV iron) and Erythropoiesis-Stimulating Agents (ESAs like Erythropoietin, Darbepoetin) to maintain haemoglobin 10–11.5 g/dL
• CKD-Mineral Bone Disease: Phosphate binders (Calcium carbonate, Sevelamer, Lanthanum carbonate) and active Vitamin D analogues (Calcitriol, Alfacalcidol)
• Metabolic Acidosis: Sodium bicarbonate supplementation to maintain serum bicarbonate above 22 mEq/L
• Hyperkalaemia: Potassium binders (Patiromer, Sodium zirconium cyclosilicate) for chronic management

UTI Management: A Widespread Clinical Challenge

Urinary tract infections are among the most common bacterial infections in India, predominantly affecting women (with a lifetime risk of 50–60%) and the elderly of both sexes. Correct diagnosis and appropriate antibiotic selection are critical.

Uncomplicated UTIs

Nitrofurantoin and Fosfomycin are preferred first-line agents for uncomplicated lower UTIs (cystitis) in women, recommended by IDSA and IDSAI guidelines due to their efficacy and relatively preserved susceptibility patterns. Trimethoprim-Sulfamethoxazole and fluoroquinolones are second-line options due to increasing resistance.

Complicated UTIs and Pyelonephritis

Complicated UTIs — including pyelonephritis, catheter-associated UTIs, and UTIs in immunocompromised patients — require urine culture-guided therapy. Parenteral antibiotics (Ceftriaxone, Piperacillin-Tazobactam) are often needed initially, with step-down to oral agents based on susceptibility results.

Benign Prostatic Hyperplasia (BPH): A Ubiquitous Condition

BPH affects approximately 50% of men over 50 and 90% of men over 80 in India. Lower urinary tract symptoms (LUTS) significantly impact quality of life. Pharmacological management is first-line for mild-to-moderate symptoms:

• Alpha-blockers (Tamsulosin, Alfuzosin, Silodosin): Rapidly improve urinary flow by relaxing smooth muscle in the prostate and bladder neck. Tamsulosin 0.4mg once daily is the most commonly prescribed agent in India.
• 5-Alpha Reductase Inhibitors (5-ARIs): Finasteride and Dutasteride reduce prostate volume over 6–12 months, preventing disease progression and reducing the risk of acute urinary retention. Most effective in men with enlarged prostates.
• Combination therapy: Alpha-blocker + 5-ARI (e.g., Tamsulosin + Dutasteride, commercially available as Duodart) is recommended for men with significant LUTS and enlarged prostates.

Kasdap Healthcare's Renal & Urology Portfolio

Kasdap Healthcare's Renal & Urology segment provides a comprehensive range including nephroprotective agents, antihypertensives, UTI treatments, BPH medications, and kidney stone management medicines — all manufactured under WHO-GMP aligned protocols and available through our pan-India distribution network.